Groundbreaking Study Confirms Clinical Decision Impact of HER2DX ® Genomic Assay in Early-Stage HER2-Positive Breast Cancer
REVEAL GENOMICS®, a pioneering Barcelona-based biotech company dedicated to advancing precision oncology, is proud to announce the publication of a groundbreaking study demonstrating the clinical impact of HER2DX®, its genomic diagnostic test designed for early-stage HER2-positive (HER2+) breast cancer.
The study, now published in ESMO Real World Data and Digital Oncology, is the first prospective real-world investigation assessing the impact of HER2DX® results on treatment decision-making in clinical practice.
The study, led by Dr. Olga Martínez-Sáez, Dr. Juan Miguel Cejalvo, and Dr. Antonio Llombart-Cussac, evaluated how HER2DX® impacted treatment decisions in a cohort of 297 patients with stage I-III HER2+ breast cancer across multiple hospitals in Spain. The primary findings reveal that HER2DX® led to a modification in the treatment plan in 48.1% of cases, with most changes (75.5%) leading to a reduction in treatment intensity, reducing chemotherapy and/or anti-HER2 without compromising outcomes.
HER2DX® also demonstrated strong predictive capability, accurately identifying patients with a higher likelihood of achieving a pathologic complete response (pCR), reinforcing its role as a crucial tool in therapy selection.
Additionally, oncologists reported a significant increase in confidence when making treatment decisions based on HER2DX® data. Finally, the study also underscored the economic benefits of incorporating HER2DX® into clinical practice, with healthcare cost savings when drug costs and type of vein access were taken into account, further validating its role in optimizing treatment strategies and reducing unnecessary interventions.
Dr. Olga Martínez Sáez, breast medical oncologist at Clinic Barcelona Comprehensive Cancer Center and Principal Investigator (PI) of the study, added: “This study represents a significant step forward in personalized oncology. HER2DX® enables physicians to make precision-guided decisions with greater confidence, improving patient care.”
Dr. Juan Miguel Cejalvo, breast medical oncologist at Hospital Clínico Universitario de Valencia/INCLIVA, and co-PI of the study, emphasized the importance of integrating genomic tools into routine clinical practice, “These results confirm that HER2DX® provides valuable information that can refine treatment strategies, allowing for more personalized care while maintaining excellent outcomes.”
Dr. Antonio Llombart-Cussac, head of the medical oncology department at Hospital Arnau de Vilanova in Valencia, and investigator of the study, highlighted the impact on clinical practice, “The capacity to forecast a patient's therapeutic response prior to treatment initiation allows oncologists to adjust treatment intensity appropriately, effectively reducing unnecessary toxicity and healthcare costs.”
Patricia Villagrasa, CEO of REVEAL GENOMICS®, underscored the company’s mission, “Our goal is to revolutionize cancer care with cutting-edge genomic insights, helping oncologists make more informed decisions and benefiting patients. The results of this first clinical utility study confirms HER2DX® as a key tool in precision medicine for HER2+ breast cancer.”
About HER2DX®
HER2DX® is the world’s first diagnostic test formulated specifically for HER2+ breast cancer. Marketed by REVEAL GENOMICS® since January 2022, HER2DX® is a standardized 27-gene expression test for patients with early-stage HER2+ breast cancer.
HER2DX® is a prognostic and, predictive assay based on clinical and genomic data. The test integrates clinical information (i.e. tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene.
HER2DX® predicts:
- Risk of relapse score (high vs. low): the risk of recurrence in patients with newly diagnosed HER2+ breast cancer.
- pCR likelihood score (high vs. medium vs. low): the likelihood of a patient responding to anti-HER2-based treatment before surgery.
- ERBB2 score (high vs. medium vs. low): the quantitative expression of ERBB2 mRNA across HER2-negative, HER2-low and HER2+ breast cancer.
About HER2+ breast cancer
HER2+ breast cancer accounts for 20% of all diagnosed breast tumors. This represents more than 390,000 new cases diagnosed worldwide every year, meaning that, on average, 3 women are diagnosed with HER2+ breast cancer every 4 minutes. HER2+ breast cancer is clinically and biologically heterogeneous, and standard clinical-pathological assessment has proven insufficient in capturing this heterogeneity. Understanding this biological heterogeneity is key to identifying the prognosis of each patient and the benefit from systemic therapies that target HER2.
About REVEAL GENOMICS®
REVEAL GENOMICS, S.L. is a biotechnology start-up dedicated to redefining the role of biomarkers in oncology. The company focuses on developing innovative diagnostic tools that optimize therapeutic decision-making for patients with cancer. By leveraging advanced genomic technologies, sophisticated computational algorithms, and machine learning, REVEAL GENOMICS® generates novel insights into cancer biology and treatment response.
The company has developed HER2DX®, TNBCDX®, and DNADX®, state-of-the-art genomic assays that provide prognostic and predictive information to guide personalized cancer treatment strategies. REVEAL GENOMICS, S.L. is a spin-off of Hospital Clínic of Barcelona, IDIBAPS, the University of Barcelona (U.B.), and the Vall d’Hebron Institute of Oncology (VHIO), bringing together expertise from leading academic and clinical institutions to advance precision oncology.
For further information visit: http://www.reveal-genomics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250310984921/en/
Contacts
Further information: Adriana Herrera, aherrera@reveal-genomics.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mori Memorial Foundation’s Global Power City Index 2025 Sees City Rankings Shift Due to Tourism Gains in East Asia and Inflationary Pressures in the West17.12.2025 04:00:00 CET | Press Release
The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today published its annual Global Power City Index (GPCI) 2025, a report evaluating the urban competitiveness of 48 major cities worldwide. The report also includes the GPCI–Financial Centers index, an assessment of cities as international financial centers, and the new GPCI–Startup Ecosystems index, which assesses the competitiveness of startup environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216187692/en/ 48 Major Cities Evaluated in Mori Memorial Foundation’s GPCI-2025 Report This year’s report highlights the remarkable rise of East Asian cities and the stagnation of several Western cities, showing how global challenges, such as geopolitical tensions and regional disparities in inflation, are greatly impacting the performance of major cities worldwide. The r
GE HealthCare and Indonesia’s Ministry of Health to expand access to quality care through the provision of 300+ advanced CT scanners17.12.2025 03:00:00 CET | Press Release
GE HealthCare (Nasdaq: GEHC) today announced it will supply more than 300 CT (computed tomography) scanners under Indonesia’s Strengthening Indonesia’s Health Referral Network (SIHREN) program to deliver equitable, high-quality care to more than 280 million Indonesians. As part of a competitively awarded, multi-year contract, GE HealthCare will supply the advanced CT scanners to public hospitals across all 38 provinces, including urban and remote areas. The CT scanner procurement under SIHREN was conducted through a fully competitive international tender process governed by the World Bank’s procurement regulations. SIHREN is the largest healthcare infrastructure investment in Indonesia’s history and among the largest multilateral health projects globally. SIHREN aims to modernize the national referral system and expand access to diagnostics and treatment across the archipelago, with a focus on non-communicable diseases (NCD) management, maternal health, and pandemic resilience. By mode
IDWS 2025 Concludes with Focus on Global Knowledge Exchange, Financial Opportunities, and Scalable Water Solutions16.12.2025 20:03:00 CET | Press Release
The 4th Innovation Driven Water Sustainability Conference (IDWS) 2025 concluded on Wednesday in Jeddah, confirming its status as one of the world’s most influential platforms for shaping the future of water innovation, sustainability, and security. Gathering senior global policymakers and international industry leaders, this year’s edition has advanced critical dialogue on safeguarding the planet’s most vital resource, with Saudi Arabia at the forefront. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216483490/en/ Investors, innovators, and global institutions gather in Saudi to outline how capital, collaboration, and governance can accelerate long term water sustainability (Photo: AETOSWire) Among the most consequential engagements were a series of meetings that brought together discussions powered by SWA, centred on shared challenges, knowledge exchange, and exploring opportunities within the global water ecosystem. Att
OAG Appoints ex-Skyscanner Executive Filip Filipov as New Chief Executive Officer16.12.2025 17:00:00 CET | Press Release
OAG announces today the appointment of Filip Filipov, ex-Skyscanner executive, as new Chief Executive Officer. Filip Filipov currently serves as the company’s Chief Operating Officer and takes over from Phil Callow who has chosen to step down having completed thirteen transformational years at the helm of OAG to pursue his many other interests. Since joining in 2024, Filipovhas played a leading role in the company’s ambitious next phase of growth and ongoing acceleration. He will now lead OAG into a new era defined by advanced data products and AI-driven intelligence. Before joining OAG, Filipov held senior roles in travel technology and big-data consulting, including on Skyscanner’s executive team. Filip Filipov said: “It’s a privilege to step into this role and lead a company with such a strong heritage and reputation. I’m excited for what’s ahead and committed to serving our customers with the reliability, service, and innovation they depend on.” Chairman of OAG, Gehan Talwatte, com
Xsolla Integrates SPENN in Rwanda and Zambia Giving Developers Access to a Strong Consumer-Merchant Ecosystem16.12.2025 16:49:00 CET | Press Release
Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced that it has added SPENN to its payments solution portfolio in Rwanda and Zambia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251216303338/en/ Xsolla Integrates SPENN In Rwanda And Zambia Giving Developers Access To A Strong Consumer-Merchant Ecosystem Both Rwanda and Zambia are mobile-first, wallet-led economies where mobile money drives financial inclusion and rapid growth in digital transactions. Reports found that approximately 86% of Rwandan adults own or have used mobile money. As of mid-2024, mobile money transaction volumes in Zambia increased by 44% to 1.4 billion transactions from mid-2023. By adding SPENN as a payment method to its portfolio, Xsolla enables players to continue paying seamlessly in a way they are already familiar with. Key benefits of the SPENN integration include: Streamline
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom